News
Media Coverage

Thursday, November 20, 2014

Ready or Not: Stem Cell Therapies Poised to Enter Trials for Alzheimer’s

see url motilium lactation robert frost essay can you buy viagra over the counter in india buy discount viagra thesis+agriculture+finance+pakistan https://austinmusicfoundation.org/papers/the-best-writing-service/2020/ https://centralvermonthumane.org/ucf-essay-help/ personal goals essay phd dissertation writing service generic viagra in mexico research paper on memory lexapro and stroke enter site source site get paid for writing essays prednisone 10 mg no prescription cialis long term https://heystamford.com/writing/essay-help-discuss/8/ https://chanelmovingforward.com/stories/essay-writing-service-in-1-hour/51/ write an essay in a day tesis ui essay writing services cheating write an essay about my home https://generationgreenwpg.com/ghostwriter-for-hire-2849/ go http://wnpv1440.com/teacher/discourse-analysis-dissertation-example/33/ japan modernization essay go follow link go to site https://www.puente.org/exams/how-do-i-know-what-generation-my-ipad-2-is/13/ AlzforumStem cells have been hailed, and hailed some more, as a breakthrough technology. All the same, they have been slow to make real inroads in the understanding and treatment of Alzheimer’s disease. That is about to change, according to scientists who spoke at “Accelerating the Cure for Alzheimer’s Disease through Regenerative Medicine.” READ MORE HERE

Wednesday, August 20, 2014

Company Uses Intravenous Stem Cells to Successfully Treat Alzheimer’s

Alzheimer's News TodayAn intravenous administration of allogeneic, human, ischemia-tolerant mesenchymal stem cells (itMSCs) in a pre-clinical animal model of Alzheimer’s disease has been successfully performed by Stemedica International, a subsidiary of Stemedica Cell Technologies developing stem cell therapies for Alzheimer’s disease and dementia. READ MORE HERE

Stemedica Posts Alzheimer’s Stem Cell Data

BioPortfolio LogoStemedica International S.A., a Stemedica Cell Technologies Inc. subsidiary developing stem cell therapies for Alzheimer’s disease and dementia, revealed the first results of an intravenous administration of allogeneic, human, ischemia-tolerant mesenchymal stem cells (itMSCs) in a pre-clinical animal model of Alzheimer’s disease. READ MORE HERE

Stemedica International Posts Alzheimer’s Stem Cell Data

DD&D MagStemedica International S.A., a Stemedica Cell Technologies Inc. subsidiary developing stem cell therapies for Alzheimer’s disease and dementia, revealed the first results of an intravenous administration of allogeneic, human, ischemia-tolerant mesenchymal stem cells (itMSCs) in a pre-clinical animal model of Alzheimer’s disease. READ MORE HERE